Risk Factors, Mechanisms and Treatments of Thromboangiitis Obliterans: An Overview of Recent Research

Author(s): Meng-di Li, Yi-fan Wang, Mei-wen Yang, Fen-fang Hong*, Shu-long Yang*

Journal Name: Current Medicinal Chemistry

Volume 27 , Issue 35 , 2020


  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Thromboangiitis obliterans (TAO) is a nonatherosclerotic thromboticocclusive vasculitis that affects the vessels of the small and medium-sized extremities. No explicit etiology or pathogenesis of TAO has been proven, and more effective treatments are needed.

Objective: The study aimed to summarize and present an overview of recent advances regarding the risk factors, mechanisms and treatments of TAO and to organize the related information in figures to provide a comparatively complete reference.

Methods: We searched PubMed for English-language literature about TAO without article type limits, including articles about the risk factors, pathological mechanisms and treatments of TAO in the last 10 years with essential supplements (references over ranges and English abstracts of Russian literature).

Results: After screening content of works of literature, 99 references were evaluated. We found that risk factors of TAO include smoking, gene factors and periodontal diseases. The underlying mechanism of TAO involves oxidative stress, immunity, hemodynamic changes, inflammation and so on. Moreover, similarities in genetic factors and cigarette relevance existed between periodontal diseases and TAO, so further study of relationship was required. For TAO treatment, medicine, endovascular intervention and revascularization surgery, autologous cell therapy and novel therapies were also mentioned. Besides, a hypothesis that infection triggers autoimmunity in TAO could be speculated, in which TLR4 plays a key role.

Conclusion: 1. A hypothesis is put forward that infections can trigger autoimmunity in TAO development, in which TLR4, as a key agent, can activate immune signaling pathways and induce autoimmune cytokines expression. 2. It is suggested to reconsider the association between periodontal diseases and TAO, as they share the same high-risk population. Controlling periodontal disease severity in TAO studies may provide new clues. 3. For TAO treatment, endovascular intervention and autologous cell therapy both showed promising long-term therapeutic effectiveness, in which autologous cell therapy is becoming more popular, although more clinical comparisons are needed.

Keywords: Thromboangiitis obliterans, buerger’s disease, risk-factors, pathological mechanism, treatments, clinical features of TAO.

[1]
Park, U.J.; Kim, D.I. Thromoboagiitis Obliterans (TAO). Int. J. Stem Cells, 2010, 3(1), 1-7.
[http://dx.doi.org/10.15283/ijsc.2010.3.1.1 ] [PMID: 24855534]
[2]
Sun, X.L.; Law, B.Y.; de Seabra Rodrigues Dias, I.R.; Mok, S.W.F.; He, Y.Z.; Wong, V.K. Pathogenesis of thromboangiitis obliterans: gene polymorphism and immunoregulation of human vascular endothelial cells. Atherosclerosis, 2017, 265, 258-265.
[http://dx.doi.org/10.1016/j.atherosclerosis.2017.08.009 ] [PMID: 28864202]
[3]
Sapkota, P.; Budhathoky, P.; Mathew, S. Smoking and Thromboangitis Obliterans- Are they related? JNMA J. Nepal Med. Assoc., 2014, 52(194), 802-805.
[http://dx.doi.org/10.31729/jnma.2755 ] [PMID: 26905708]
[4]
Fazeli, B.; Rafatpanah, H.; Ravari, H.; Farid Hosseini, R.; Tavakol Afshari, J.; Hamidi Alamdari, D.; Valizadeh, N.; Moheghi, N.; Rezaee, S.A. Sera of patients with thromboangiitis obliterans activated cultured human umbilical vein endothelial cells (HUVECs) and changed their adhesive properties. Int. J. Rheum. Dis., 2014, 17(1), 106-112.
[http://dx.doi.org/10.1111/1756-185X.12214 ] [PMID: 24472273]
[5]
Dellalibera-Joviliano, R.; Jacob-Ferreira, A.L.; Joviliano, E.E.; Tanus-Santos, J.E.; Evora, P.R. Imbalanced matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 activities in patients with thromboangiitis obliterans. Vasc. Med., 2012, 17(2), 73-78.
[http://dx.doi.org/10.1177/1358863X11435979 ] [PMID: 22402936]
[6]
Park, H.S.; Cho, K.H.; Kim, K.L.; Kim, D.K.; Lee, T. Reduced circulating endothelial progenitor cells in thromboangiitis obliterans (Buerger’s disease). Vasc. Med., 2013, 18(6), 331-339.
[http://dx.doi.org/10.1177/1358863X13513935 ] [PMID: 24292638]
[7]
Hewing, B.; Stangl, V.; Stangl, K.; Enke-Melzer, K.; Baumann, G.; Ludwig, A. Circulating angiogenic factors in patients with thromboangiitis obliterans. PLoS One, 2012, 7(4)e34717
[http://dx.doi.org/10.1371/journal.pone.0034717 ] [PMID: 22506045]
[8]
Fazeli, B.; Rafatpanah, H.; Ravari, H.; Hosseini, R.F.; Rezaee, S.A. Investigation of the expression of mediators of neovascularization from mononuclear leukocytes in thromboangiitis obliterans. Vascular, 2014, 22(3), 174-180.
[http://dx.doi.org/10.1177/1708538113477068 ] [PMID: 23567329]
[9]
Le Joncour, A.; Soudet, S.; Dupont, A.; Espitia, O.; Koskas, F.; Cluzel, P.; Hatron, P.Y.; Emmerich, J.; Cacoub, P.; Resche-Rigon, M.; Lambert, M.; Saadoun, D. French Buerger’s Network. Long-Term Outcome and Prognostic Factors of Complications in Thromboangiitis Obliterans (Buerger’s Disease): A Multicenter Study of 224 Patients. J. Am. Heart Assoc., 2018, 7(23)e010677
[http://dx.doi.org/10.1161/JAHA.118.010677 ] [PMID: 30571594]
[10]
Shi, Z.F.; Fang, Q.B.; Limu, S.; Jiareke, T.; Ge, X.H. Association between three SNPs and thromboangiitis obliterans in Xinjiang Uyghur population. Genet. Test. Mol. Biomarkers, 2016, 20(2), 55-62.
[http://dx.doi.org/10.1089/gtmb.2015.0264 ] [PMID: 26829209]
[11]
Chen, Z.; Nakajima, T.; Inoue, Y.; Kudo, T.; Jibiki, M.; Iwai, T.; Kimura, A. A single nucleotide polymorphism in the 3-untranslated region of MyD88 gene is associated with Buerger’s disease but not with Takayasu arteritis in Japanese. J. Hum. Genet., 2011, 56(7), 545-547.
[http://dx.doi.org/10.1038/jhg.2011.44 ] [PMID: 21525878]
[12]
Chen, Z.; Takahashi, M.; Naruse, T.; Nakajima, T.; Chen, Y.W.; Inoue, Y.; Ishikawa, I.; Iwai, T.; Kimura, A. Synergistic contribution of CD14 and HLA loci in the susceptibility to Buerger’s disease. Hum. Genet., 2007, 122(3-4), 367-372.
[http://dx.doi.org/10.1007/s00439-007-0408-1 ] [PMID: 17653770]
[13]
Adigzel, Y.; Yilmaz, E.; Akar, N. Effect of eNOS and ET-1 polymorphisms in thromboangiitis obliterans. Clin. Appl. Thromb. Hemost., 2010, 16(1), 103-106.
[http://dx.doi.org/10.1177/1076029609336854 ] [PMID: 19520685]
[14]
Masoudian, M.; Fazeli, B.; Sharebiani, H.; Rajabnejad, A.; Ravari, H.; Akbarin, M.M.; Dadgarmoghaddam, M. Association of the five gene related endothelial cell dysfunction polymorphisms with Buergers disease development. Int. Angiol., 2016, 35(2), 205-211.
[PMID: 26406963]
[15]
Pavlic, V.; Vujic-Aleksic, V.; Zubovic, N.; Gojkov-Vukelic, M. Periodontitis and Buergers disease: recent advances. Acta Inform. Med., 2013, 21(4), 250-252.
[http://dx.doi.org/10.5455/aim.2013.21.250-252 ] [PMID: 24554799]
[16]
Aoyama, N.; Suzuki, J.; Ogawa, M.; Watanabe, R.; Kobayashi, N.; Hanatani, T.; Ashigaki, N.; Sekinishi, A.; Izumi, Y.; Isobe, M. Toll-like receptor-2 plays a fundamental role in periodontal bacteria-accelerated abdominal aortic aneurysms. Circ. J., 2013, 77(6), 1565-1573.
[http://dx.doi.org/10.1253/circj.CJ-12-1191 ] [PMID: 23412709]
[17]
Suzuki, J.; Aoyama, N.; Ogawa, M.; Hirata, Y.; Izumi, Y.; Nagai, R.; Isobe, M. Periodontitis and cardiovascular diseases. Expert Opin. Ther. Targets, 2010, 14(10), 1023-1027.
[http://dx.doi.org/10.1517/14728222.2010.511616 ] [PMID: 20678026]
[18]
Alamdari, D.H.; Ravarit, H.; Tavallaie, S.; Fazeli, B. Oxidative and antioxidative pathways might contribute to thromboangiitis obliterans pathophysiology. Vascular, 2014, 22(1), 46-50.
[http://dx.doi.org/10.1177/1708538112473979 ] [PMID: 23518834]
[19]
He, T.; Qu, B.H.; Wang, D.L.; Hu, M. Hypoxia-inducible factor-1 expression in the different stages of rat thromboangiitis obliterans. Genet. Mol. Res., 2015, 14(2), 6715-6722.
[http://dx.doi.org/10.4238/2015.June.18.15 ] [PMID: 26125880]
[20]
Aliee, A.; Zahedi Avval, F.; Taheri, H.; Moghadam, S.M.; Soukhtanloo, M.; Hamidi Alamdari, D.; Fazeli, B. The Status of Nitric Oxide and its Backup, Heme Oxygenase 1, in Thromboangiitis Obliterans. Rep. Biochem. Mol. Biol., 2018, 6(2), 197-202.
[PMID: 29766003]
[21]
Fen-fang, H.; Fa-xian, G.; Ying, Z.; Qin-hua, M.; Da-lei, Z.; Bei, Y.; Wei-ying, Z.; Lei, W.; Zhi-ping, W.; Hui, L.; Shu-long, Y. Shenfu injection protects human ECV304 cells from hydrogen peroxide via its anti-apoptosis way. J. Ethnopharmacol., 2015, 163, 203-209.
[http://dx.doi.org/10.1016/j.jep.2015.01.032 ] [PMID: 25660381]
[22]
Morrow, J.D.; Frei, B.; Longmire, A.W.; Gaziano, J.M.; Lynch, S.M.; Shyr, Y.; Strauss, W.E.; Oates, J.A.; Roberts, L.J. II Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N. Engl. J. Med., 1995, 332(18), 1198-1203.
[http://dx.doi.org/10.1056/NEJM199505043321804 ] [PMID: 7700313]
[23]
Joviliano, E.E.; Dellalibera-Joviliano, R.; Dalio, M.; Evora, P.R.; Piccinato, C.E. Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans - current practices. Int. J. Angiol., 2009, 18(3), 119-125.
[http://dx.doi.org/10.1055/s-0031-1278337 ] [PMID: 22477511]
[24]
Ketha, S.S.; Cooper, L.T. The role of autoimmunity in thromboangiitis obliterans (Buergers disease). Ann. N. Y. Acad. Sci., 2013, 1285(1), 15-25.
[http://dx.doi.org/10.1111/nyas.12048 ] [PMID: 23510296]
[25]
Klein-Weigel, P.F.; Bimmler, M.; Hempel, P.; Schöpp, S.; Dreusicke, S.; Valerius, J.; Bohlen, A.; Boehnlein, J.M.; Bestler, D.; Funk, S.; Elitok, S. G-protein coupled receptor auto-antibodies in thromboangiitis obliterans (Buergers disease) and their removal by immunoadsorption. Vasa, 2014, 43(5), 347-352.
[http://dx.doi.org/10.1024/0301-1526/a000372 ] [PMID: 25147011]
[26]
Dellalibera-Joviliano, R.; Joviliano, E.E.; Silva, J.S.; Evora, P.R.B. Activation of cytokines corroborate with development of inflammation and autoimmunity in thromboangiitis obliterans patients. Clin. Exp. Immunol., 2012, 170(1), 28-35.
[http://dx.doi.org/10.1111/j.1365-2249.2012.04624.x ] [PMID: 22943198]
[27]
Dellalibera-Joviliano, R.; Joviliano, E.E.; Evora, P.R. Determination of kininogens levels and kallikrein/kininase II activities in patients with thromboangiitis obliterans. Scand. J. Immunol., 2010, 72(2), 128-133.
[http://dx.doi.org/10.1111/j.1365-3083.2010.02408.x ] [PMID: 20618771]
[28]
Azizi, M.; Boutouyrie, P.; Bura-Rivière, A.; Peyrard, S.; Laurent, S.; Fiessinger, J.N. Thromboangiitis obliterans and endothelial function. Eur. J. Clin. Invest., 2010, 40(6), 518-526.
[http://dx.doi.org/10.1111/j.1365-2362.2010.02294.x ] [PMID: 20584171]
[29]
Fujii, Y.; Fujimura, N.; Mikami, S.; Maruhashi, T.; Kihara, Y.; Chayama, K.; Noma, K.; Higashi, Y. Flow-mediated vasodilation is augmented in a corkscrew collateral artery compared with that in a native artery in patients with thromboangiitis obliterans (Buerger disease). J. Vasc. Surg., 2011, 54(6), 1689-1697.
[http://dx.doi.org/10.1016/j.jvs.2011.05.095 ] [PMID: 21908145]
[30]
Kong, X.; Yuan, H.; Wu, X.; Zhang, J.; Zhou, H.; Wang, M.; Liu, Y.; Jin, X. High-mobility-group box protein 1A box reduces development of sodium laurate-induced thromboangiitis obliterans in rats. J. Vasc. Surg., 2013, 57(1), 194-204.
[http://dx.doi.org/10.1016/j.jvs.2012.06.083 ] [PMID: 23069071]
[31]
Xu, Y.; Zhang, R.; Chen, J.; Zhang, Q.; Wang, J.; Hu, J.; Guan, X.; Jin, L.; Fu, H.; Gui, B.; Guo, Y.; Li, S. Urocortin promotes the development of vasculitis in a rat model of thromboangiitis obliterans via corticotrophin-releasing factor type 1 receptors. Br. J. Pharmacol., 2009, 157(8), 1368-1379.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00210.x ] [PMID: 19572944]
[32]
Undas, A.; Nowakowski, T.; Ciela-Dul, M.; Sadowski, J. Abnormal plasma fibrin clot characteristics are associated with worse clinical outcome in patients with peripheral arterial disease and thromboangiitis obliterans. Atherosclerosis, 2011, 215(2), 481-486.
[http://dx.doi.org/10.1016/j.atherosclerosis.2010.12.040 ] [PMID: 21324459]
[33]
De Caridi, G.; Bitto, A.; Massara, M.; Pallio, G.; Pizzino, G.; Serra, R.; Altavilla, D.; Squadrito, F.; Spinelli, F. Increased serum HMGB-1, ICAM-1 and metalloproteinase-9 levels in Buergers patients. Curr. Vasc. Pharmacol., 2016, 14(4), 382-387.
[http://dx.doi.org/10.2174/1570161114666160303111355 ] [PMID: 26935815]
[34]
Wei, Z.; Jiang, W.; Wang, H.; Li, H.; Tang, B.; Liu, B.; Jiang, H.; Sun, X. The IL-6/STAT3 pathway regulates adhesion molecules and cytoskeleton of endothelial cells in thromboangiitis obliterans. Cell. Signal., 2018, 44, 118-126.
[http://dx.doi.org/10.1016/j.cellsig.2018.01.015 ] [PMID: 29339086]
[35]
Mohareri, M.; Mirhosseini, A.; Mehraban, S.; Fazeli, B. Thromboangiitis obliterans episode: autoimmune flare-up or reinfection? Vasc. Health Risk Manag., 2018, 14, 247-251.
[http://dx.doi.org/10.2147/VHRM.S172047 ] [PMID: 30319267]
[36]
Guo, H.; Sun, L.; Ling, S.; Xu, J.W.; Levistilide, A. Levis-tilide A Ameliorates NLRP3 Expression Involving the Syk-p38/JNK Pathway and Peripheral Obliterans in Rats. Mediators Inflamm., 2018, 20187304096
[http://dx.doi.org/10.1155/2018/7304096] [PMID: 30158835]
[37]
Guzel, E.; Topal, E.; Yildirim, A.; Atilla, P.; Akkus, M. Targeting novel antigens in the arterial wall in thromboangiitis obliterans. Folia Histochem. Cytobiol., 2010, 48(1), 134-141.
[http://dx.doi.org/10.2478/v10042-008-0104-6] [PMID: 20529829]
[38]
Slavov, E.S.; Stanilova, S.A.; Petkov, D.P.; Dobreva, Z.G. Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin. Exp. Rheumatol., 2005, 23(2), 219-226.
[PMID: 15895893]
[39]
Funk, C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 2001, 294(5548), 1871-1875.
[http://dx.doi.org/10.1126/science.294.5548.1871 ] [PMID: 11729303]
[40]
Font-Nieves, M.; Sans-Fons, M.G.; Gorina, R.; Bonfill-Teixidor, E.; Salas-Prdomo, A.; Mrquez-Kisinousky, L.; Santalucia, T.; Planas, A.M. Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J. Biol. Chem., 2012, 287(9), 6454-6468.
[http://dx.doi.org/10.1074/jbc.M111.327874 ] [PMID: 22219191]
[41]
Umar, A.; Zhou, W.; Abdusalam, E.; Tursun, A.; Reyim, N.; Tohti, I.; Moore, N. Effect of Ocimum basilicum L. on cyclo-oxygenase isoforms and prostaglandins involved in thrombosis. J. Ethnopharmacol., 2014, 152(1), 151-155.
[http://dx.doi.org/10.1016/j.jep.2013.12.051 ] [PMID: 24412551]
[42]
Zhang, R.; Xu, Y.; Fu, H.; Wang, J.; Jin, L.; Li, S. Urocortin induced expression of COX-2 and ICAM-1 via corticotrophin-releasing factor type 2 receptor in rat aortic endothelial cells. Br. J. Pharmacol., 2009, 158(3), 819-829.
[http://dx.doi.org/10.1111/j.1476-5381.2009.00346.x ] [PMID: 19694731]
[43]
Yang, H.; Tracey, K.J. Targeting HMGB1 in inflammation. Biochim. Biophys. Acta, 2010, 1799(1-2), 149-156.
[http://dx.doi.org/10.1016/j.bbagrm.2009.11.019 ] [PMID: 19948257]
[44]
Liu, C.; Kong, X.; Wu, X.; Wang, X.; Guan, H.; Wang, H.; Wang, L.; Jin, X.; Yuan, H. Alleviation of A disintegrin and metalloprotease 10 (ADAM10) on thromboangiitis obliterans involves the HMGB1/RAGE/NF-B pathway. Biochem. Biophys. Res. Commun., 2018, 505(1), 282-289.
[http://dx.doi.org/10.1016/j.bbrc.2018.09.002 ] [PMID: 30245136]
[45]
Kong, X.; Yuan, H.; Wu, X.; Zhang, J.; Zhou, H.; Wang, M.; Liu, Y.; Jin, X. High-Mobility-Group Box Protein 1 A Box Reduces Devel-opment of Sodium Laurate-Induced Thromboangiitis Obliter-ans in Rats 1, 194-204..
[46]
Darnige, L.; Helley, D.; Fischer, A.M.; Emmerich, J.; Smadja, D.M.; Fiessinger, J.N. Platelet microparticle levels: a biomarker of thromboangiitis obliterans (Buergers disease) exacerbation. J. Cell. Mol. Med., 2010, 14(1-2), 449-451.
[http://dx.doi.org/10.1111/j.1582-4934.2009.00928.x ] [PMID: 19818096]
[47]
Dang, Y.; Xia, Y.; Li, Y.; Yu, D. W. The Prolonged Clotting Time in Two Female Patients with Thromboangiitis Obliterans The Prolonged Clotting Time in Two Female Patients with Thromboangiitis Obliterans, 2013.199-203..
[48]
Liu, Q.; Zhou, H.C.; Yang, X.L.; Zhao, Y.P.; Luo, H.P.; He, C.W.; Wan, X.B. Embolus-carried vascular endothelial cell growth factor 165 improves angiogenesis in thromboangiitis obliterans. Genet. Mol. Res., 2014, 13(1), 1744-1752.
[http://dx.doi.org/10.4238/2014.March.17.2 ] [PMID: 24668662]
[49]
Klein-Weigel, P.; Volz, T.S.; Zange, L.; Richter, J. Buergers disease: providing integrated care. J. Multidiscip. Healthc., 2016, 9, 511-518.
[http://dx.doi.org/10.2147/JMDH.S109985 ] [PMID: 27785045]
[50]
Zerbino, D. D.; Zimba, E. A.; Bagry, N. N. Thromboangiitis Obliterans (Buerger’s Disease): State of the Art] Angiologiia i sosudistaia khirurgiia = Angiology and vascular surgery, 2016, 22(4), 185..
[51]
Vijayakumar, A.; Tiwari, R.; Kumar Prabhuswamy, V. Thromboangiitis obliterans (buergers disease)-current practices. Int. J. Inflamm., 2013, 2013(12)156905
[PMID: 24102033]
[52]
Cacione, D.G.; Baptista-Silva, J.C. Pharmacological Treat-ment for Buergers Disease; John Wiley & Sons, Ltd, 2014.
[53]
Galyfos, G.; Kerasidis, S.; Kastrisios, G.; Giannakakis, S.; Sachmpazidis, I.; Anastasiadou, C.; Geropapas, G.; Pa-papetrou, A.; Papacharalampous, G.; Maltezos, C. Conserva-tive Treatment of Patients with Thromboangiitis Obliterans or Cannabis-Associated Arteritis Presenting with Critical Lower Limb Ischaemia; Vasa-european Journal of Vascular Medi-cine, 2017, pp. 1-5.
[54]
Palomo-Arellano, A.; Cervigón-González, I.; Torres-Iglesias, L.M. Effectiveness of bosentan in the treatment of ischemic lesions in a case of thromboangiitis obliterans (Buerger disease): a case report. Dermatol. Online J., 2011, 17(7), 4.
[PMID: 21810389]
[55]
Todoli Parra, J.A.; Hernndez, M.M.; Arrébola López, M.A. Efficacy of bosentan in digital ischemic ulcers. Ann. Vasc. Surg., 2010, 24(5), 690.e1-690.e4.
[http://dx.doi.org/10.1016/j.avsg.2010.03.011 ] [PMID: 20579585]
[56]
Narvez, J.; Garcia-Gomez, C. lvarez, L.; Santo, P.; Aparicio, M.; Pascual, M.; López de Recalde, M.; Borrell, H.; Nolla, J.M. Efficacy of bosentan in patients with refractory thromboangiitis obliterans (Buerger disease): a case series and review of the literature. Medicine (Baltimore), 2016, 95(48)e5511
[http://dx.doi.org/10.1097/MD.0000000000005511 ] [PMID: 27902617]
[57]
Yong, J.; Zhang, S.; Gao, Y.; Guo, W.; Shi, P.; Zhou, Q. Effects of aspirin combined with cilostazol on thromboangiitis obliterans in diabetic patients. Exp. Ther. Med., 2018, 16(6), 5041-5046.
[http://dx.doi.org/10.3892/etm.2018.6833 ] [PMID: 30546409]
[58]
Song, F.; Ji, B.; Chen, T. Cilostazol on the expression of ICAM-1, VCAM-1 and inflammatory factors in plasma in patients with thromboangiitis obliterans. Exp. Ther. Med., 2018, 16(3), 2349-2354.
[http://dx.doi.org/10.3892/etm.2018.6436 ] [PMID: 30186478]
[59]
Li, Y.L.; Xin, X.M.; Chang, Z.Y.; Shi, R.J.; Miao, Z.M.; Ding, J.; Hao, G.P. The endophytic fungi of Salvia miltiorrhiza Bge.f. alba are a potential source of natural antioxidants. Bot. Stud. (Taipei, Taiwan), 2015, 56(1), 5.
[http://dx.doi.org/10.1186/s40529-015-0086-6 ] [PMID: 28510814]
[60]
Hong, F.; He, C.; Liu, X.; Tu, G.; Guo, F.; Yang, S. Protective effect of Shenfu injection on thromboangiitis obliterans model rats. J. Ethnopharmacol., 2011, 138(2), 458-462.
[http://dx.doi.org/10.1016/j.jep.2011.09.033 ] [PMID: 21982791]
[61]
Li, Q.L.; He, D.H.; Huang, Y.H.; Niu, M. Thromboangiitis obliterans in two brothers. Exp. Ther. Med., 2013, 6(2), 317-320.
[http://dx.doi.org/10.3892/etm.2013.1160 ] [PMID: 24137181]
[62]
Chang; Yaowen; Fenqiang; Wang; Wenhui; Song; Laichang; Zhengfei; Dongjun; Zhaoliang. Integrated treatment for lower-limb stage H thromboangiitis obliterans by interventional therapy and oral administration of Chinese medicine: a randomized controlled clinical trial. J. Tradit. Chin. Med., 2015, 35(1), 41.
[http://dx.doi.org/10.1016/S0254-6272(15)30007-8 ] [PMID: 25842727]
[63]
Kawarada, O.; Kume, T.; Ayabe, S.; Nakaya, T.; Nakai, M.; Nishimura, K.; Noguchi, T.; Yokoi, Y.; Ogawa, H.; Yasuda, S. Endovascular therapy outcomes and intravascular ultrasound findings in thromboangiitis obliterans (Buergers Disease). J. Endovasc. Ther., 2017, 24(4), 504-515.
[http://dx.doi.org/10.1177/1526602817710917 ] [PMID: 28743226]
[64]
Modaghegh, M.S.; Hafezi, S. Endovascular treatment of thromboangiitis obliterans (Buergers Disease). Vasc. Endovascular Surg., 2018, 52(2), 124-130.
[http://dx.doi.org/10.1177/1538574417744085 ] [PMID: 29237360]
[65]
Kim, D.H.; Ko, Y.G.; Ahn, C.M.; Shin, D.H.; Kim, J.S.; Kim, B.K.; Choi, D.; Hong, M.K.; Jang, Y. Immediate and late outcomes of endovascular therapy for lower extremity arteries in Buerger disease. J. Vasc. Surg., 2018, 67(6), 1769-1777.
[http://dx.doi.org/10.1016/j.jvs.2017.09.020 ] [PMID: 29157680]
[66]
Firat, A.; Igus, B. Endovascular recanalization of thromboangiitis obliterans (Buergers disease) in twenty-eight consecutive patients and combined antegrade-retrograde intervention in eight patients. Cardiovasc. Intervent. Radiol., 2019, 42(6), 820-828.
[http://dx.doi.org/10.1007/s00270-019-02193-x ] [PMID: 30834476]
[67]
Li, F.Q.; Li, L.; He, X.W.; Zhang, M.X.; Wang, W. Percutaneous transluminal angioplasty combined with intraarterial thrombolysis to treat lower-extremity arterial occlusion in thromboangitis. Int. Angiol., 2016, 35(5), 440-445.
[PMID: 26406966]
[68]
Lee, C.Y.; Choi, K.; Kwon, H.; Ko, G.Y.; Han, Y.; Kwon, T.W.; Cho, Y.P. Outcomes of endovascular treatment versus bypass surgery for critical limb ischemia in patients with thromboangiitis obliterans. PLoS One, 2018, 13(10)e0205305
[http://dx.doi.org/10.1371/journal.pone.0205305 ] [PMID: 30300407]
[69]
Kacmaz, F.; Kaya, A.; Keskin, M.; Keceoglu, S.; Algin, I.H.; Yilmazkaya, B.; Ilkay, E. Clinical outcomes of extended endovascular recanalization of 16 consecutive Buerger’s disease patients. Vascular, 2019, 27(3), 233-241.
[http://dx.doi.org/10.1177/1708538118805623] [PMID: 30305010]
[70]
Graziani, L.; Morelli, L.; Parini, F.; Franceschini, L.; Spano, P.; Calza, S.; Sigala, S. Clinical outcome after extended endovascular recanalization in Buergers disease in 20 consecutive cases. Ann. Vasc. Surg., 2012, 26(3), 387-395.
[http://dx.doi.org/10.1016/j.avsg.2011.08.014 ] [PMID: 22285343]
[71]
Tang, J.; Gan, S.; Zheng, M.; Jiang, Y.; Feng, Y.; Miao, J. Efficacy of endovascular radiofrequency ablation for thromboangiitis obliterans (buergers disease). Ann. Vasc. Surg., 2017, 42, 78-83.
[http://dx.doi.org/10.1016/j.avsg.2016.11.012 ] [PMID: 28341508]
[72]
Nakae, R.; Matsuzaki, S.; Egawa-Takata, T.; Mimura, K.; Kanagawa, T.; Kimura, T. Pregnancy management for a patient with graft occlusion after right iliac artery bypass surgery. J. Obstet. Gynaecol. Res., 2015, 41(6), 979-984.
[http://dx.doi.org/10.1111/jog.12636 ] [PMID: 25511914]
[73]
Gwon, J.G.; Kwon, Y.J.; Han, Y.J.; Cho, Y.P.; Kwon, T.W. Chronic Nonatherosclerotic Occlusive Popliteal Artery Disease. Ann. Vasc. Surg., 2018, 47, 128-133.
[http://dx.doi.org/10.1016/j.avsg.2017.07.037 ] [PMID: 28887249]
[74]
Wu, S.; Sun, X.; Wu, W.; Shi, D.; Jiang, T. Effect of revascularization on IL-6 and TNF-? in patients with thromboangiitis obliterans. Exp. Ther. Med., 2018, 15(4), 3947-3951.
[http://dx.doi.org/10.3892/etm.2018.5877 ] [PMID: 29556267]
[75]
Patwa, J.J.; Krishnan, A. Buergers Disease (Thromboangiitis Obliterans)- Management by Ilizarovs Technique of Horizontal Distraction. A Retrospective Study of 60 Cases. Indian J. Surg., 2011, 73(1), 40-47.
[http://dx.doi.org/10.1007/s12262-010-0186-1 ] [PMID: 22211037]
[76]
Kulkarni, S.; Kulkarni, G.; Shyam, A.K.; Kulkarni, M.; Kulkarni, R.; Kulkarni, V. Management of thromboangiitis obliterans using distraction osteogenesis: A retrospective study. Indian J. Orthop., 2011, 45(5), 459-464.
[http://dx.doi.org/10.4103/0019-5413.83954 ] [PMID: 21886930]
[77]
Kothari, R.; Sharma, D.; Thakur, D.S.; Kumar, V.; Somashekar, U. Thoracoscopic dorsal sympathectomy for upper limb Buergers disease. JSLS, 2014, 18(2), 273-276.
[http://dx.doi.org/10.4293/108680813X13753907292755 ] [PMID: 24960492]
[78]
Matoba, S.; Tatsumi, T.; Murohara, T.; Imaizumi, T.; Katsu-da, Y.; Ito, M.; Saito, Y.; Uemura, S.; Suzuki, H.; Fukumo-to, S.; Yamamoto, Y.; Onodera, R.; Teramukai, S.; Fuku-shima, M.; Matsubara, H. TACT Follow-up Study Investiga-tors. Long-term clinical outcome after intramuscular implan-tation of bone marrow mononuclear cells (Therapeutic Angi-ogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am. Heart J., 2008, 156(5), 1010-1018.
[http://dx.doi.org/10.1016/j.ahj.2008.06.025 ] [PMID: 19061721]
[79]
Guo, J.; Guo, L.; Cui, S.; Tong, Z.; Dardik, A.; Gu, Y. Autologous bone marrow-derived mononuclear cell therapy in Chinese patients with critical limb ischemia due to thromboangiitis obliterans: 10-year results. Stem Cell Res. Ther., 2018, 9(1), 43.
[http://dx.doi.org/10.1186/s13287-018-0784-6 ] [PMID: 29471870]
[80]
Motukuru, V.; Suresh, K.R.; Vivekanand, V.; Raj, S.; Girija, K.R. Therapeutic angiogenesis in Buergers disease (thromboangiitis obliterans) patients with critical limb ischemia by autologous transplantation of bone marrow mononuclear cells. J. Vasc. Surg., 2008, 48(6)(Suppl.), 53S-60S.
[http://dx.doi.org/10.1016/j.jvs.2008.09.005 ] [PMID: 19084740]
[81]
Kondo, K.; Yanishi, K.; Hayashida, R.; Shintani, S.; Shibata, R.; Murotani, K.; Ando, M.; Mizuno, M.; Fujiwara, T.; Murohara, T.; Matoba, S. TACT Follow-up Study Investigators. Long-Term Clinical Outcomes Survey of Bone Marrow-Derived Cell Therapy in Critical Limb Ischemia in Japan. Circ. J., 2018, 82(4), 1168-1178.
[http://dx.doi.org/10.1253/circj.CJ-17-0510 ] [PMID: 29386474]
[82]
Moriya, J.; Minamino, T.; Tateno, K.; Shimizu, N.; Kuwabara, Y.; Sato, Y.; Saito, Y.; Komuro, I. Long-term outcome of therapeutic neovascularization using peripheral blood mononuclear cells for limb ischemia. Circ. Cardiovasc. Interv., 2009, 2(3), 245-254.
[http://dx.doi.org/10.1161/CIRCINTERVENTIONS.108.799361 ] [PMID: 20031722]
[83]
Aoyama, N.; Nishinari, M.; Ohtani, S.; Kanai, A.; Noda, C.; Hirata, M.; Miyamoto, A.; Watanabe, M.; Minamino, T.; Izumi, T.; Ako, J. Clinical features and predictors of patients with critical limb ischemia who responded to autologous mononuclear cell transplantation for therapeutic angiogenesis. Heart Vessels, 2017, 32(9), 1099-1108.
[http://dx.doi.org/10.1007/s00380-017-0968-5 ] [PMID: 28357515]
[84]
Lee, K.B.; Kang, E.S.; Kim, A.K.; Kim, M.H.; Do, Y.S.; Park, K.B.; Park, H.S.; Um, S.H.; Cho, S.W.; Kim, D.I. Stem cell therapy in patients with thromboangiitis obliterans: assessment of the long-term clinical outcome and analysis of the prognostic factors. Int. J. Stem Cells, 2011, 4(2), 88-98.
[http://dx.doi.org/10.15283/ijsc.2011.4.2.88 ] [PMID: 24298340]
[85]
Wan, J.; Yang, Y.; Ma, Z.H.; Sun, Y.; Liu, Y.Q.; Li, G.J.; Zhang, G.M. Autologous peripheral blood stem cell transplantation to treat thromboangiitis obliterans: preliminary results. Eur. Rev. Med. Pharmacol. Sci., 2016, 20(3), 509-513.
[PMID: 26914127]
[86]
Dong, Z.; Pan, T.; Fang, Y.; Wei, Z.; Gu, S.; Fang, G.; Liu, Y.; Luo, Y.; Liu, H.; Zhang, T.; Hu, M.; Guo, D.; Xu, X.; Chen, B.; Jiang, J.; Yang, J.; Shi, Z.; Zhu, T.; Shi, Y.; Liu, P.; Fu, W. Purified CD34+ cells versus peripheral blood mononuclear cells in the treatment of angiitis-induced no-option critical limb ischaemia: 12-Month results of a prospective randomised single-blinded non-inferiority trial. EBioMedicine, 2018, 35, 46-57.
[http://dx.doi.org/10.1016/j.ebiom.2018.08.038 ] [PMID: 30172703]
[87]
Chiang, Y.H.; Lin, C.C.; Chen, Y.C.; Lee, O.K. Treatment of Arsenite Intoxication-Induced Peripheral Vasculopathy with Mesenchymal Stem Cells. Int. J. Mol. Sci., 2018, 19(4)E1026
[http://dx.doi.org/10.3390/ijms19041026 ] [PMID: 29596344]
[88]
Martin-Rufino, J.D.; Lozano, F.S.; Redondo, A.M.; Villaron, E.M.; Rueda, R.; Fernandez-Samos, R.; Sanchez-Guijo, F. Sequential intravenous allogeneic mesenchymal stromal cells as a potential treatment for thromboangiitis obliterans (Buergers disease). Stem Cell Res. Ther., 2018, 9(1), 150.
[http://dx.doi.org/10.1186/s13287-018-0901-6 ] [PMID: 29848379]
[89]
Kim, A.K.; Kim, M.H.; Kim, S.; Oh, W.; Hong, H.K.; Kang, K.S.; Kim, B.S.; Kim, D.I. Stem-cell therapy for peripheral arterial occlusive disease. Eur. J. Vasc. Endovasc. Surg., 2011, 42(5), 667-675.
[http://dx.doi.org/10.1016/j.ejvs.2011.06.026 ] [PMID: 21764609]
[90]
Oda, M.; Toba, K.; Ozawa, T.; Kato, K.; Yanagawa, T.; Ikarashi, N.; Takayama, T.; Suzuki, T.; Hanawa, H.; Fuse, I.; Nakata, K.; Narita, M.; Takahashi, M.; Aizawa, Y. Establishment of culturing system for ex-vivo expansion of angiogenic immature erythroid cells, and its application for treatment of patients with chronic severe lower limb ischemia. J. Mol. Cell. Cardiol., 2010, 49(3), 347-353.
[http://dx.doi.org/10.1016/j.yjmcc.2010.04.001 ] [PMID: 20382155]
[91]
Lee, H.C.; An, S.G.; Lee, H.W.; Park, J.S.; Cha, K.S.; Hong, T.J.; Park, J.H.; Lee, S.Y.; Kim, S.P.; Kim, Y.D.; Chung, S.W.; Bae, Y.C.; Shin, Y.B.; Kim, J.I.; Jung, J.S. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia: a pilot study. Circ. J., 2012, 76(7), 1750-1760.
[http://dx.doi.org/10.1253/circj.CJ-11-1135 ] [PMID: 22498564]
[92]
Cacione, D.G.; do Carmo Novaes, F.; Moreno, D.H. Stem cell therapy for treatment of thromboangiitis obliterans (Buerger’s disease). Cochrane Database Syst. Rev., 2018, 10(10)CD012794
[93]
Baumann, G.; Stangl, V.; Klein-Weigel, P.; Stangl, K.; Laule, M.; Enke-Melzer, K. Successful treatment of thromboangiitis obliterans (Buergers disease) with immunoadsorption: results of a pilot study. Clin. Res. Cardiol., 2011, 100(8), 683-690.
[http://dx.doi.org/10.1007/s00392-011-0298-z ] [PMID: 21380608]
[94]
Hemsinli, D.; Kaplan, S.T.; Kaplan, S.; Yildirim, F. Hyperbaric Oxygen Therapy in the Treatment of Fontaine Stage IV Thromboangiitis Obliterans. Int. J. Low. Extrem. Wounds, 2016, 15(4), 366-370.
[http://dx.doi.org/10.1177/1534734616666866 ] [PMID: 27647524]
[95]
Hemsinli, D.; Altun, G.; Kaplan, S.T.; Yildirim, F.; Cebi, G. Hyperbaric oxygen treatment in thromboangiitis obliterans: a retrospective clinical audit. Diving Hyperb. Med., 2018, 48(1), 31-35.
[http://dx.doi.org/10.28920/dhm48.1.31-35 ] [PMID: 29557099]
[96]
Abeles, A.M.; Nicolescu, M.; Pinchover, Z.; Abeles, M. Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors. Vascular, 2014, 22(4), 313-316.
[http://dx.doi.org/10.1177/1708538113502648 ] [PMID: 24000082]
[97]
Hashimoto, T.; Koyama, H.; Miyata, T.; Hosaka, A.; Tabata, Y.; Takato, T.; Nagawa, H. Selective and sustained delivery of basic fibroblast growth factor (bFGF) for treatment of peripheral arterial disease: results of a phase I trial. Eur. J. Vasc. Endovasc. Surg., 2009, 38(1), 71-75.
[http://dx.doi.org/10.1016/j.ejvs.2009.02.005 ] [PMID: 19328029]
[98]
Kumagai, M.; Marui, A.; Tabata, Y.; Takeda, T.; Yamamoto, M.; Yonezawa, A.; Tanaka, S.; Yanagi, S.; Ito-Ihara, T.; Ikeda, T.; Murayama, T.; Teramukai, S.; Katsura, T.; Matsubara, K.; Kawakami, K.; Yokode, M.; Shimizu, A.; Sakata, R. Safety and efficacy of sustained release of basic fibroblast growth factor using gelatin hydrogel in patients with critical limb ischemia. Heart Vessels, 2016, 31(5), 713-721.
[http://dx.doi.org/10.1007/s00380-015-0677-x ] [PMID: 25861983]
[99]
Kinane, D.F.; Hart, T.C. Genes and gene polymorphisms associated with periodontal disease. Crit. Rev. Oral Biol. Med., 2003, 14(6), 430-449.
[http://dx.doi.org/10.1177/154411130301400605 ] [PMID: 14656898]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 27
ISSUE: 35
Year: 2020
Published on: 28 October, 2020
Page: [6057 - 6072]
Pages: 16
DOI: 10.2174/0929867326666190816233042
Price: $65

Article Metrics

PDF: 40
HTML: 2